PKCα overexpression has been described in lung, breast, and prostate cancer, and high-grade glioma and melanoma, among others [24,30,33,35,38,41], and it is generally associated with therapy resistance and exacerbated tumor cell proliferation [23,31]. The gene discussed is PRKCA; the disease is melanoma.